These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

268 related items for PubMed ID: 20145676

  • 1. Therapeutic exon skipping for dysferlinopathies?
    Aartsma-Rus A, Singh KH, Fokkema IF, Ginjaar IB, van Ommen GJ, den Dunnen JT, van der Maarel SM.
    Eur J Hum Genet; 2010 Aug; 18(8):889-94. PubMed ID: 20145676
    [Abstract] [Full Text] [Related]

  • 2. Efficient bypass of mutations in dysferlin deficient patient cells by antisense-induced exon skipping.
    Wein N, Avril A, Bartoli M, Beley C, Chaouch S, Laforêt P, Behin A, Butler-Browne G, Mouly V, Krahn M, Garcia L, Lévy N.
    Hum Mutat; 2010 Feb; 31(2):136-42. PubMed ID: 19953532
    [Abstract] [Full Text] [Related]

  • 3. Designing Effective Antisense Oligonucleotides for Exon Skipping.
    Shimo T, Maruyama R, Yokota T.
    Methods Mol Biol; 2018 Feb; 1687():143-155. PubMed ID: 29067661
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Identification of Novel Antisense-Mediated Exon Skipping Targets in DYSF for Therapeutic Treatment of Dysferlinopathy.
    Lee JJA, Maruyama R, Duddy W, Sakurai H, Yokota T.
    Mol Ther Nucleic Acids; 2018 Dec 07; 13():596-604. PubMed ID: 30439648
    [Abstract] [Full Text] [Related]

  • 9. Antisense-Mediated Skipping of Dysferlin Exons in Control and Dysferlinopathy Patient-Derived Cells.
    Verwey N, Gazzoli I, Krause S, Mamchaoui K, Mouly V, Aartsma-Rus A.
    Nucleic Acid Ther; 2020 Apr 07; 30(2):71-79. PubMed ID: 31873062
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Direct Reprogramming of Human DMD Fibroblasts into Myotubes for In Vitro Evaluation of Antisense-Mediated Exon Skipping and Exons 45-55 Skipping Accompanied by Rescue of Dystrophin Expression.
    Lee JJA, Saito T, Duddy W, Takeda S, Yokota T.
    Methods Mol Biol; 2018 Apr 07; 1828():141-150. PubMed ID: 30171539
    [Abstract] [Full Text] [Related]

  • 12. An Overview of Recent Advances and Clinical Applications of Exon Skipping and Splice Modulation for Muscular Dystrophy and Various Genetic Diseases.
    Rodrigues M, Yokota T.
    Methods Mol Biol; 2018 Apr 07; 1828():31-55. PubMed ID: 30171533
    [Abstract] [Full Text] [Related]

  • 13. Dysferlin Exon 32 Skipping in Patient Cells.
    Barthélémy F, Courrier S, Lévy N, Krahn M, Bartoli M.
    Methods Mol Biol; 2018 Apr 07; 1828():489-496. PubMed ID: 30171562
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Bioinformatic and functional optimization of antisense phosphorodiamidate morpholino oligomers (PMOs) for therapeutic modulation of RNA splicing in muscle.
    Popplewell LJ, Graham IR, Malerba A, Dickson G.
    Methods Mol Biol; 2011 Apr 07; 709():153-78. PubMed ID: 21194027
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.